Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN

(BIIB)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/17/2019 05/20/2019 05/21/2019 05/22/2019 05/23/2019 Date
229.28(c) 230.76(c) 232.92(c) 235.04(c) 229.11(c) Last
1 893 279 2 004 443 1 531 118 1 477 994 2 103 648 Volume
-0.69% +0.65% +0.94% +0.91% -2.52% Change
More quotes
Financials (USD)
Sales 2019 13 902 M
EBIT 2019 7 118 M
Net income 2019 5 356 M
Finance 2019 3 490 M
Yield 2019 -
Sales 2020 13 806 M
EBIT 2020 7 089 M
Net income 2020 5 268 M
Finance 2020 7 351 M
Yield 2020 -
P/E ratio 2019 8,43
P/E ratio 2020 8,40
EV / Sales2019 3,03x
EV / Sales2020 2,77x
Capitalization 45 573 M
More Financials
Company
Biogen is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (84.4%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; -... 
Sector
Pharmaceuticals
Calendar
06/11Presentation
More about the company
Surperformance© ratings of Biogen
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN
05/22BIOGEN : to Present at Bernstein's 35th Annual Strategic Decisions Conference
AQ
05/20BIOGEN : Recommends Stockholders Reject the Below-market Mini-tender Offer by TR..
AQ
05/15BIOGEN : SPINRAZA Receives Positive Recommendation from NICE for Funding in the ..
AQ
05/15BIOGEN INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/14BIOGEN : NHS England, Biogen reach deal on pricey drug for deadly disorder
RE
05/14BIOGEN : SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for F..
AQ
05/13BIOGEN : Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401..
PR
05/10BIOGEN : Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401..
PR
05/08BIOGEN : Data at AAN Demonstrate Biogen's Leadership and Commitment to Innovatio..
AQ
05/08BIOGEN : Data at AAN Demonstrate Biogens Leadership and Commitment to Innovation..
AQ
More news
Analyst Recommendations on BIOGEN
More recommendations
Sector news : Biopharmaceuticals
01:09pGLAXOSMITHKLINE : GSK brings back bonuses for some sales reps
RE
12:59pGLAXOSMITHKLINE : GSK's shingles vaccine approved for use in China in adults age..
RE
11:31aNOVARTIS : CEO says data quality, lagging innovation crimp China M&A
RE
11:30aNOVARTIS : CEO says data quality, lagging innovation crimp China M&A
RE
10:31aGLAXOSMITHKLINE : GSK to change incentives for sales representatives
RE
More sector news : Biopharmaceuticals
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 259 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Michael D. Ehlers Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN-23.86%45 573
CSL LIMITED11.62%64 459
ALEXION PHARMACEUTICALS31.01%28 601
SAMSUNG BIOLOGICS CO LTD--.--%16 896
GRIFOLS1.88%16 046
BIOMARIN PHARMACEUTICAL INC.2.14%15 703